1. Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RARα isoforms: a study of the PETHEMA group.
- Author
-
González, M., Barragán, E., Bolufer, P., Chillón, C., Colomer, D., Borstein, R., Calasanz, M. J., Gómez-Casares, M. T., Villegas, A., Marugán, I., Román, J., Martín, G., Rayón, C., Debén, G., Tormo, M., Díaz-Mediavilla, J., Esteve, J., González-San Miguel, J., Rivas, C., and Pérez-Equiza, K.
- Subjects
TRANSCRIPTION factors ,ACUTE myeloid leukemia ,GENETICS - Abstract
Of 167 newly diagnosed acute promyelocytic leukaemia patients, 83 patients were long (L)-form (50%), eight variable (V)-form (5%) and 76 short (S)-form (45%). The V-form and S-form groups presented a significantly higher percentage of patients with white blood cell counts > 10 × 10
9 /l (P < 0·05). The S-form cases displayed a significantly higher number of cases with M3v microgranular features (P = 0·005) and CD34 expression (P < 0·0001). There were no differences between the three isoforms in complete remission (CR) rate (overall CR 90%), but the 3-year disease-free survival was lower for V-form cases than it was for L- and S-form cases (62% vs. 94% and 89%, P = 0·056). We conclude that the V-form and S-form types are associated with some negative prognostic features at diagnosis. However, our data were only able to demonstrate an association with adverse prognosis in the V-form type and, moreover, as the number of cases was limited, needs to be confirmed in large, uniformly treated series. [ABSTRACT FROM AUTHOR]- Published
- 2001
- Full Text
- View/download PDF